WebMD

Tremfya: First Fully Under-the-Skin IL-23 Inhibitor Shot Approved for Ulcerative Colitis and Crohn’s Disease

What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...
Nasdaq

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
Seeking Alpha

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...
Seeking Alpha

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...